Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director · Chief Operating Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-04-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-04-20 · Conversion · Acquired 320,511 · Balance 650,032 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Row 2 · 2026-04-20 · Conversion · Acquired 72,853 · Balance 722,885 F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Row 3 · 2026-04-20 · Other · Disposed 722,885 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. |
| Common StockSEC Table I · non-derivative | Direct | 760,105 |
Ending reported balance
After 2026-04-20 transaction · row 5
2 source rows · reconciled sequenceRow 4 · 2026-04-20 · Other · Acquired 722,885 · Balance 722,885 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Row 5 · 2026-04-20 · Grant · Acquired 37,220 · Balance 760,105 F4: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F5: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-20 · Other · Disposed 300,883 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 300,883 |
Reported balance
After 2026-04-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-20 · Other · Acquired 300,883 · Balance 300,883 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-20 · Other · Disposed 12,190 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
| Class A Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-20 · Conversion · Disposed 247,311 · Balance 0 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Founders Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-20 · Conversion · Disposed 73,200 · Balance 0 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-20 · Conversion · Disposed 176,160 · Balance 0 F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 12,190 |
Reported balance
After 2026-04-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-04-20 · Other · Acquired 12,190 · Balance 12,190 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
F4: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F5: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 12,190 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 13 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,190 Underlying: Common Stock · 12,190 shares Expires 2036-01-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 12,190 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 12 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 12,190 shares Expires 2036-01-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 300,883 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 11 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,883 Underlying: Common Stock · 300,883 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 300,883 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 10 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 300,883 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionSeries A-1 Preferred Stock · Derivative | 176,160 | $0.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 9 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 72,853 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · derivative.exercise_date: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · derivative.expiration_date: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionFounders Preferred Stock · Derivative | 73,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 8 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 73,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.exercise_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.expiration_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass A Common Stock · Derivative | 247,311 | $0.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 7 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 247,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.exercise_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.expiration_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantCommon Stock | 37,220 | $0.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · nonDerivative · entry 5 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,105 F4 · kind: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherCommon Stock | 722,885 | $0.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · nonDerivative · entry 4 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,885 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherClass B Common Stock | 722,885 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · nonDerivative · entry 3 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass B Common Stock | 72,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · nonDerivative · entry 2 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · price: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass B Common Stock | 320,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · nonDerivative · entry 1 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 16, 2026 Filed Apr 21, 2026 00:34 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantStock Option (Right to Buy) · Derivative | 163,358 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002126944-26-000004 · form4-04212026_120439.xml · derivative · entry 6 Chen Shiping · CIK 0002126944 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,358 Underlying: Common Stock · 163,358 shares Expires 2036-04-15 F5 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.